This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA® is indicated for the treatment of complicated intra-abdominal infections1*

ZAVICEFTA is as effective as a carbapenem when combined with metronidazole in patients with cIAI caused by Gram-negative pathogens2

RECLAIM Phase III trial: 1066 hospitalised adults with cIAI

Patients with favourable clinical response at TOC (%)§

Baseline pathogens: E. coli, K. pneumoniae and P. aeruginosa including some ceftazidime-resistant strains. 417 patients (40%) had polymicrobial infection at baseline.

Explore more

REPRISE Phase III trial:

333 hospitalised adults with a cUTI or cIAI

View trial results

RECAPTURE Phase III trial:

1033 hospitalised adults with cUTI.

View trial results

REPROVE Phase III trial:

879 hospitalised adults with HAP and VAP

View trial results

§Non-inferiority was considered met if the lower limit of the 95% CI for between-group difference was greater than the prespecified non-inferiority margin of –12.5%.
†Patients in the MITT population are defined as patients who received study drug and met the clinical disease criteria.
*Consideration should be given to official guidance on the appropriate use of antibacterial agents

Abbreviations:

AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; HAP, hospital-acquired pneumonia; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas aeruginosa; TOC, test of cure; VAP, ventilator-associated pneumonia; cIAI, complicated intra-abdominal infection; E.coli, Escherichia coli; MITT, modified intention-to-treat; cUTI, complicated urinary tract infection.

Prescribing information

Zavicefta (ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion

Meronem® (meropenem triydrate) IV 1g

Meronem® (meropenem triydrate) IV 500mg

Tygacil® (tigecycline) 50mg Powder for Solution for Infusion

References:
  1. ZAVICEFTA. Summary of Product Characteristics;
  2. Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9.
PP-ZVA-GBR-1288. September 2021

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

Professor Jonathan Edgeworth

Professor Jonathan Edgeworth, Consultant Microbiologist from Guy's and St. Thomas' NHS Trust talks about the benefit of new antibiotics to treat CRE. He also presents his experience using ceftazidime-avibactam in a patient in intensive care with MDR Klebsiella.

Card CTA

** This is an optional area where footnotes can live.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No